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Abstract
Background: The treatment of oral squamous cell carcinomas (OSCC) and human osteosarcoma (HOS) includes
surgery and/or radiotherapy which often lead to reduced quality of life. This study was aimed to study the
antiproliferative activity of local honey (Tualang) on OSCC and HOS cell lines.
Methods: Several concentrations of Tualang honey (1% - 20%) were applied on OSCC and HOS cell lines for 3, 6,
12, 24, 48 and 72 hours. Morphological characteristics were observed under light and fluorescent microscope. Cell
viability was assessed using MTT assay and the optical density for absorbance values in each experiment was
measured at 570 nm by an ELISA reader. Detection of cellular apoptosis was done using the Annexin V-FITC
Apoptosis Detection Kit.
Results: Morphological appearance showed apoptotic cellular changes like becoming rounded, reduction in cell
number, blebbed membrane and apoptotic nuclear changes like nuclear shrinkage, chromatin condensation and
fragmented nucleus on OSCC and HOS cell lines. Cell viability assay showed a time and dose-dependent inhibitory
effect of honey on both cell lines. The 50% inhibitory concentration (IC50) for OSCC and HOS cell lines was found
to be 4% and 3.5% respectively. The maximum inhibition of cell growth of ≥80% was obtained at 15% for both
cell lines. Early apoptosis was evident by flow cytometry where percentage of early apoptotic cells increased in
dose and time dependent manner.
Conclusion: Tualang honey showed antiproliferative effect on OSCC and HOS cell lines by inducing early
apoptosis.
Background
Cancer of the oral cavity is eleventh most common
malignancy worldwide [1] while in the Indian subconti-
nent and regions of Southeast Asia, it is the predomi-
nant malignancy accounting for up to 40% of all the
cancers [2]. This high incidence of oral cancer is pri-
marily attributable to the habit of tobacco, betel quid
chewing and alcohol consumption [3].
Oral squamous cell carcinomas (OSCC) are the most
common type of oral cancers. Similarly, Human Osteo-
sarcomas (HOS) that arise from the jaw, account for
2.1% of all malignant oral and maxillofacial tumours
[4]. The treatment of these types of oral cancers
includes surgery and/or radiotherapy, which are often
associated with loss of function, disfigurement and
reduced quality of life [5]. Recently, advances in che-
motherapeutic agents for the treatment of OSCCs have
been highlighted but the survival rate of patients has
not improved significantly. The development of novel
therapeutic agents targeting the malignant behaviour
of these cancers is important to improve the prognosis
of treatment [6]. The study of molecular mechanisms
of chemotherapeutic agents and the combination of
chemotherapeutic agents that induce synergistic antic-
ancer activity are necessary to improve clinical out-
comes [7].
Many researchers have studied the anticancer activities
of drugs or herbal extracts on OSCC cell lines. These
include Tamoxifen in combination with Cisplatin [7], 5-
Fluorouracil [8], Cordycepin [9], Scutellaria baicalensis
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any medium, provided the original work is properly cited.[10], Quercetin [11] Artemisinin [12] and others. Simila-
rily, Ginsenoside Rg1, Cinnamic acid, and Tanshinone
IIA [13], Diosgenin[14], Venenum Bufonis and Oxgall
powder[15] have been shown to have antiproliferative
effect on HOS cell lines.
Honey is a food product which is collected from var-
ious plants and processed by honey bees (Apis melli-
fera). Honey has been used as traditional medicine for
centuries in different cultures, not only for its nutri-
tional value but also its healing properties. Recently,
honey has been tested and approved scientifically for its
functional and biological properties like anti-oxidant,
anti-inflammatory, anti-bacterial, anti-viral, anti-ulcerous
activities, anti-lipid and anti-cancer properties [16-23].
These activities are mainly attributed to the phenolic
compounds such as flavonoids having antioxidant prop-
erties and radical scavenging activities seen among all
types of honeys in different proportions, depending on
the geographical areas, source of honeybee food and cli-
mate [24-26].
Honey has also been used in palliative care of various
cancers like in radiation-induced mucositis, radiotherapy
and chemotherapy induced skin reactions and wounds
[27]. It has also been shown to produce antiproliferative
effects in bladder cancer [21], colon cancer [28], mam-
mary carcinoma and fibrosarcoma [22]. However, till
date no study has been found to show antiproliferative
effects of honey on oral cancers.
Malaysian Tualang honey is collected from the honey
combs of Asian rock bees (Apis dorsata), which build
their hives high up in the Tualang tree (Koompassia
excelsa). Tualang honey is used commonly as a medic-
inal product [29] and as a food in Malaysia. Recently,
antibacterial properties of this honey have been studied
and compared with other honeys [30,31]. However, its
antiproliferative properties are yet to be studied. The
purpose of the current study was to investigate the anti-
proliferative activity of Malaysian Tualang honey on
OSCC and HOS cell lines.
Methods
Honey
Local Malaysian honey (Tualang honey), which was
donated by the Food and Agricultural Ministry (FAMA),
was used in this study. Working concentrations of
honey were prepared fresh for each experiment by serial
dilution with culture medium after which each concen-
tration was filtered using 0.20 μm sterile filter unit (Sar-
torius stedim).
Cell culture materials
OSCC cell lines were purchased from American Tissue
Collection Centre (ATCC) (CRL-1623) and were main-
tained in Dulbecco’s Modified Eagle’s Medium (DMEM)
and Ham’s F12 (DMEM/F12) (Sigma-Aldrich, USA).
HOS cell lines were purchased from ATCC (CRL-1543)
and were maintained in DMEM high glucose 1× (Gibco®
invitrogen USA). Culture media was supplemented with
10% Foetal Bovine Serum (FBS) and 1% penicillin/strep-
tomycin (Gibco® invitrogen).
Morphological analysis under light and fluorescent
microscopy
For morphological analysis, OSCC and HOS cell lines
were seeded in 60-mm dishes at 5 × 10
5 cells/ml. The
cells were treated with 2% and 10% concentration of
Tualang honey for 24, 48 and 72 hours. At the indicated
time points, morphological changes were examined and
recorded under light microscope (Carl Zeiss, Germany).
Apoptosis was also determined morphologically at simi-
lar intervals and concentrations after staining the cells
with Hoechst 33258 (Sigma-Aldrich) at a concentration
of 20 μg/ml in PBS and incubated for 30 minutes. The
cells were observed in the dark using Axioplan 2 fluor-
escent microscope (Carl Zeiss, Germany) at 356 nm.
MTT cell viability assay
OSCC and HOS cell lines were seeded in 96-well plate
(Nunc™, Denmark) containing 1 × 10
4 cells with 100 μl
serum medium. After the cells reached 70-80% conflu-
ence, they were treated with serum free medium
containing Tualang honey concentrations from 1% to
20% for 3, 6, 12, 24 and 48 hours for all concentrations.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium
bromide or MTT (Calbiochem, Germany) was added at
different time points with the final concentration of 0.5
mg/ml and then incubated for 4 hours at 37°C. The
medium was removed and Dimethyl Sulphoxide
(DMSO) (Ajax Finechem Pty Ltd, Australia) was added
to dissolve the crystals by shaking the plate weakly for
15 minutes in the dark [9]. The optical density (O.D.) of
each treatment was measured at 570 nm by an ELISA
reader (Sunrise, Tecan). Each experiment was performed
in triplicates. Considering control untreated cells (cells
without Tualang honey) as having 100% proliferation
rate, the proliferation of cancer cells was expressed as
the % cytoviability using the following formula: %
cytoviability = A570 of treated cells/A570 of control
cells × 100% [32].
Non-peroxidase, acidity and osmolar activity
Non-peroxidase activity of Tualang honey was measured
by diluting it to 25% (w/v) by taking 1 ml of honey and
adding it to either 1 ml of sterile purified water (total
activity) or 1 ml of catalase solution. The 8000 U cata-
lase solution (Sigma, C9322: 2950 units/mg) was used to
remove all the hydrogen peroxide present in the honey.
The removal of hydrogen peroxide was verified
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ity of honey concentrations and culture medium was
measured by pH 211 meter (Hanna instruments, USA).
Osmolar control solution was prepared by mixing sugars
namely 4 g fructose, 3 g glucose, 0.2 g sucrose and 0.8 g
maltose mixed for 1 hour at 80°C to make in total
10 ml of the solution with distilled water. The solution
was adjusted to be of the same osmolarity as that of
honey concentrations by using an osmometer (Gonatec,
Germany).
Cell apoptosis assay by flow cytometry
Cellular apoptosis was determined using the Annexin
V-FITC Apoptosis Detection Kit I (Clontech Labora-
tories Inc, USA) according to the manufacturer’sp r o t o -
col. OSCC and HOS cell lines were cultured at 6 × 10
5
cells/ml and seeded in 60 mm dish. The cells were trea-
ted with free medium containing various concentrations
of Tualang honey for 6, 12 and 24 hour. Cells were har-
vested by trypsinization, then washed twice with cold
PBS and centrifuged at 1000 rpm. About 1 × 10
5 -1×
10
6 cells were then resuspended in 400 μl1 ×b i n d i n g
buffer, centrifuged again at 1000 rpm for 5 minutes and
then supernatant was removed. Cells were re-suspended
in 200 μl 1× binding buffer and transferred to a sterile
flow cytometry glass tube. Five μl Annexin V-FITC and
10 μl propidium iodide were added and then incubated
in the dark at room temperature. Cells were analyzed
by flow cytometer (FACSCalibur, Becton-Dickinson,
USA) at 488 nm. The distribution of cells was analyzed
using CellQuest™ software (Becton-Dickinson) in the
flow cytometer within 1 hour of staining. Data from
10,000 cells was collected for each data file. Apoptotic
cells were identified as Annexin V-FITC-positive and
P-negative cells.
Statistical analysis
The data from MTT assay was analyzed by SPSS soft-
ware version 12.0.1 and the results were expressed as
median (IQR) of three independent experiments. As the
data was not normally distributed and the assumption
for equal variances was not fulfilled, Kruskal-Wallis test
was applied. The pairwise comparison was analyzed
using Mann-Whitney test and Bonferroni correction was
applied. The difference in the median between the dif-
ferent concentrations and time points was considered to
be statistically significant if the p-value was <0.05.
Results
Morphological changes in OSCC and HOS cell lines under
light microscopy
In both cell lines, cells without Tualang honey treatment
showed polygonal shape, which is considered as the nor-
mal cell growth phenomenon. However, when the cells
were treated with 2% and 10% honey for 24, 48 hours
and 72 hours, the cells rounded up and showed reduc-
tion in number. Cells with blebbed membrane could
also be recognized (Fig. 1). These are the morphological
changes typically seen in apoptosis [9,34]. These changes
suggested that Tualang honey had induced apoptotic
cell death in OSCC and HOS cell lines.
Morphological changes in OSCC and HOS cell lines under
fluorescence microscopy
In honey treated cell lines, morphological alteration
such as nuclear shrinkage, chromatin condensation and
fragmented nucleus were observed (Fig 2). These mor-
phological changes were characteristic of apoptotic cells.
Effect of Tualang honey on cell viability
The honey concentration required for the 50% inhibi-
tion of cell growth (IC50) was calculated after 3, 6, 12,
24 and 48 hours of exposure to honey. After 2 days of
culture, the honey IC50 of OSCC cell lines was higher
than that of HOS cells, at 4% and 3.5% respectively.
These results clarify the time and dose dependent inhi-
bitory effect of Tualang honey on both cell lines. The
maximum inhibition of cell growth of ≥80% was
obtained at 15% for both OSCC cell lines and HOS cell
lines as shown in Fig 3a and Fig 3b respectively.
Non-peroxidase, acidity and osmolar activity
MTT assay for non-peroxidase activity of honey showed
a similar effect as shown by various honey concentra-
tions, suggesting that this antiproliferative effect was
due to various other constituents of honey rather than
hydrogen peroxide (Fig. 4A). The effect of acidity of
honey was excluded as the pH of blank growth media
was found to be similar to the pH of 3.5% honey. The
pH of most of the honey concentrations used was
within the normal pH range for cell line culture. Anti-
proliferative effect of honey was found to be more than
the osmolar control solution of the same concentration
(Fig. 4B).
Cell apoptosis assay results
The dual parameter fluorescent dot plots (Fig 5) shows
the viable cell population in quadrant 3 (negative
annexin-FITC and negative PI), the cells at the early
apoptosis are in quadrant 1 (positive annexin-FITC and
negative PI) while the ones at the late apoptosis are in
quadrant 2 (positive annexin-FITC and positive PI) [35].
As seen in fig 5, control untreated cells were mostly
alive whereas when the honey treatment was applied,
the early apoptotic cells percentage increased in relation
to its concentration. The box plot percentages of cell
populations revealed that effect was dose and time
dependent.
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Page 3 of 8Figure 2 Morphological changes in nucleus seen in (a) OSCC and (b) HOS cell lines following treatment with 2% and 10% Tualang
honey for 24, 48 and 72 hrs. Cells were stained with Hoechst 33258 and observed under fluorescence microscope.
Figure 1 Effect of Tualang honey on morphology of (a) OSCC and (b) HOS cell lines as seen under light microscope. Cells were cultured
in 6-well plates until 70-80% confluence and then treated with Tualang honey 2% and 10% for 24, 48 and 72 hrs
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Honey, a part of traditional medicine, has recently
become the focus of attention for treating certain dis-
eases as well as promoting overall health and well being.
Several honey types from different floral sources and
geographical regions have been reported to contain
many phenolic compounds, which act as antioxidants
and exhibit anti-carcinogenic, anti-inflammatory, anti-
microbial, anti-atherogenic, anti-thrombotic, immune
modulating and analgesic activities [36,37]. In the oral
health setting, honey has been found to be effective for
the treatment of radiation-induced oral mucositis [38],
stomatitis [39], reducing plaque and periodontal gum
disease [40] and is also found to be anticariogenic [41].
In this study, we investigated the antiproliferative and
apoptotic activities of Malaysian Tualang honey on
human OSCC and HOS cell lines. This honey was cho-
sen for the study as antiproliferative effects of this type
of honey have not yet been verified on any type of the
cancer cell lines. Additionally, in pure unprocessed
honey like Tualang honey, there are a number of volatile
compounds reported that may be missed in processing
and fractionation [21]. This is the first study to report
the antiproliferative activity of honey on OSCC and
HOS cell lines.
While most of the previous studies on honey have
focused on its anti-microbial and wound healing proper-
ties, only few papers have looked into the anticarcino-
genic properties of honey. Gribel and Pashinskii (1990)
reported that honey revealed moderate antitumor and
pronounced antimetastatic effects. Honey was also seen
to potentiate the antitumor activity of 5-fluorouracil and
cyclophosphamide [42]. Wang et al. studied the anti-
mutagenic effects of different types of honey against a
commonly encountered dietary mutagen Trp-p-1 and
found that all honeys exhibited significant inhibition of
mutagenicity against this compound [20]. In another
study, bee honey was found to be an effective agent for
Figure 3 Graph with error bars showing antiproliferative effect of Tualang honey concentrations on (A) OSCC and (B) HOS cell lines.
Cells were seeded onto 96-well plate at 1 × 10
4/well and were treated with Tualang honey at different concentrations. Cell viability was
determined by MTT assay after 3, 6, 12, 24 and 48 hour of treatment. Time and dose dependent growth inhibition in both cell lines was
observed.
Figure 4 Graph with error bars comparing the effects of peroxidase activity and osmolality of honey. (A) MTT assay for non-peroxidase
activity of honey. Similar effect as shown by various honey concentrations was seen. (B) Effect of different concentrations of honey on the
proliferation rate of HOS cell lines in comparison to analogue osmolar solution controls. Antiproliferative effect of honey was found to be more
than its analogue osmolar solution.
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in vitro, and bladder cancer implanted mice models
in vivo [21]. A study done on tumour development and
metastasis in murine tumour models using various
honey-bee products showed an important role in con-
trolling tumour growth and metastasis in mammary car-
cinoma and a methylcholanthrene-induced fibrosarcoma
in mouse [22].
The present study showed that unfractionated Tualang
honey has potential time and dose dependent antiproli-
ferative effect on OSCC and HOS cancer cell lines. We
found that IC50 for Tualang honey was 4% for OSCC
and 3.5% for HOS cell lines. Non-peroxidase activity of
honey was found to show the same effect as shown by
various honey concentrations. Further, results of confir-
matory experiments ruled out the low pH effect of
honey as the reason for its antiproliferative activity.
Similarly, the inhibitory effect of honey was found to be
more than the effect of analogous osmolar solutions.
Thus, hydrogen peroxide activity, acidity and hyperos-
molarity of honey were ruled out for its inhibitory effect
on these cancer cell lines. A recent article suggested
that the polyphenols found in honey, like Caffeic acid,
Caffeic acid phenyl esters, Chrysin, Galangin, Quercetin,
Kaempferol, Acacetin, Pinocembrin, Pinobanksin and
Apigenin, to be promising pharmacological agents in the
treatment of cancer by reviewing their antiproliferative
and molecular mechanisms [43]. These compounds have
been shown to exhibit an inhibitory effect on tumour
cell proliferation and transformation by the down regu-
lation of many cellular enzymatic pathways including
protein tyrosine kinase, cycloxygenase and ornithine
decarboxylase pathways [44]. Another study done on
jungle honey obtained from the tropical forest of Nigeria
showed that this type of honey possessed chemotactic
activity for neutrophils, which were found to possess
potent antitumour activity mediated by reactive oxygen
species (ROS) [45].
Figure 5 Apoptotic effects of Tualang honey on (a) OSCC and (b) HOS cell lines were determined by flow cytometry analysis using
annexin V-FITC and propidium iodide. The experiments were performed after treatment with 2% and 5% honey for 6, 12 and 24 hrs. Cell
populations in bottom left, bottom right, top right and top left quadrants represented the proportion of viable cells, necrotic cells, late apoptotic
cells and early apoptotic respectively.
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concentration of honey was increased, the percentage of
early apoptotic cells also increased. For this reason, the
mode of cell death appears to be due to early apoptosis
cell death pathway. These apopototic changes were also
visible in the morphological studies which were done
using light and fluorescent microscopy where mem-
brane blebs, chromatin and nuclear condensation, DNA
fragmentation and formation of apoptotic bodies were
seen. A change in the status of the intracellular non-
protein thiol, fall in MMP and increased ROS genera-
tion were reported to occur during apoptosis [46].
Moreover, the expression of various proapoptotic and
antiapoptotic proteins was found to be altered during
apoptosis [47]. A recent study done to understand the
molecular mechanism of honey in colon cancer cell
growth inhibition found that honey induced apoptosis
was accompanied by up-regulating the p53 and modu-
lating the expression of pro and anti-apoptotic proteins
[48]. They also reported that unfractionated honey
induced cell-growth arrest, resulting in cell cycle block-
age at the sub-G1 phase. Further, it transduced the
apoptotic signal via initial depletion of intracellular non-
protein thiols (GSH), consequently reducing the MMP
and increasing the ROS generation. Similar studies need
to be done in OSCC and HOS cell lines to confirm
these findings.
Conclusion
In conclusion, the results of this study suggest that Tua-
lang honey has a promising antiproliferative and apopto-
tic effect on OSCC and HOS cell lines. Early apoptosis
could be attributed, in part, to its ability to inhibit pro-
liferation. Further investigations are needed to deter-
mine the molecular mechanisms involved in apoptosis.
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